Chronic lymphocytic leukemia: recent advances and emerging therapeutic strategies. [PDF]
Jung J.
europepmc +1 more source
Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]
Tu J +7 more
europepmc +1 more source
BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]
Robak T, Wolska-Washer A, Robak P.
europepmc +1 more source
Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study. [PDF]
Eyre TA +31 more
europepmc +1 more source
Efficacy of high-frequency low-dose rituximab and acalabrutinib in chronic lymphocytic leukemia. [PDF]
Chu CC +11 more
europepmc +1 more source
Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors. [PDF]
Schulze FJ +8 more
europepmc +1 more source
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. [PDF]
Ermann DA +12 more
europepmc +1 more source
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience. [PDF]
Duminuco A +21 more
europepmc +1 more source
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. [PDF]
Shadman M +9 more
europepmc +1 more source
Continuous or fixed-duration BTK inhibitor treatment for WM. [PDF]
Yi S, Qiu L.
europepmc +1 more source

